

## Lion TCR clinches 'Most Promising Cell & Gene Therapy Startup in Asia' Award

19 September 2022 | News


Represents the industry's affirmation of the company's achievements in immunotherapy



Singapore-based Lion TCR Pte Ltd, a clinical-stage biotech company specialized in the development and commercialisation of its proprietary engineered T Cell Receptor (TCR) products against infectious disease and its associated cancers, has been recognised as the 'Most Promising Cell & Gene Therapy Startup in Asia' category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022, organised by IMAPAC.

The award ceremony was held in conjunction with the 6th Cell & Gene Therapy World Asia 2022 conference on 14th – 15th of September at the Sheraton Tower in Singapore. Lion TCR managed to distinguish itself from other companies to win the recognition of the judges and industry leaders.

### **Conference Presentation and Award Ceremony**



**Dr Sarene Koh, Director of Technology and Manufacturing, receiving 'Most Promising Cell & Gene Therapy Startup in Asia' award.**

Lion TCR's R&D Director Dr Wai Lu-En presented on 'Advances in Liver Cancer Therapy Using our First-In-Class TCR-T Therapy' as an invited speaker during the conference. Director of Technology and Manufacturing, Dr Sarene Koh, represented Lion TCR to receive the certificate and trophy for the 'Most Promising Cell & Gene Therapy Startup in Asia' award. Dr Wai Lu-En and Dr Sarene Koh are both A\*STAR scholars, who obtained their PhDs from the prestigious Stanford University and Karolinska Institute respectively. They are the founding team members of the company, and joined Lion TCR's scientific founder, Professor Antonio Bertolotti in the research and development of T-cell immunotherapy and the immunopathogenesis of hepatitis B virus infection. Dr Wai leads Lion TCR's efforts to expand the TCR library and pipeline project, while Dr Koh leads Lion TCR's efforts on product development and process optimisation in T cell immuno-therapy.

Clinching the 'Most Promising Cell & Gene Therapy Startup in Asia' award represents the industry's affirmation of the company's achievements in immunotherapy. Lion TCR has obtained the world's first Phase 1b/2 IND approval from the US FDA for its First-In-Class autologous TCR-T cell product (LioCyx-M004) for the treatment of HBV-related hepatocellular carcinoma (HCC). FDA has also granted Lion TCR the dual designations of Fast Track and Orphan Drug Designations (ODD) due to the novelty of LioCyx-M004 treatment and its efficacy in Phase I trials. Lion TCR's endeavours to accelerate the pace of development and bring its products to patients faster.